BioCentury
ARTICLE | Clinical News

Synribo omacetaxine mepesuccinate regulatory update

October 29, 2012 7:00 AM UTC

FDA granted accelerated approval to an NDA from Teva for Synribo omacetaxine mepesuccinate to treat chronic or accelerated phase chronic myelogenous leukemia in patients who have resistance and/or int...